iTeos Therapeutics Future Growth
Future criteria checks 2/6
iTeos Therapeutics is forecast to grow earnings and revenue by 24.5% and 64.6% per annum respectively while EPS is expected to grow by 28.6% per annum.
Key information
24.5%
Earnings growth rate
28.6%
EPS growth rate
Biotechs earnings growth | 24.1% |
Revenue growth rate | 64.6% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 13 May 2024 |
Recent future growth updates
Recent updates
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 25iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
Jan 10Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%
May 13Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding
Mar 21The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically
Aug 12iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04
Aug 10iTeos Therapeutics: Too Many Unknowns
Jul 27News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts
May 11Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic
Nov 25We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth
Aug 24iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share
Aug 15GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler
Jun 15We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth
Feb 07Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?
Dec 16iTeos Therapeutics EPS misses by $0.11
Nov 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 116 | -164 | N/A | N/A | 4 |
12/31/2025 | 8 | -241 | -121 | -118 | 5 |
12/31/2024 | N/A | -167 | -126 | -123 | 3 |
3/31/2024 | N/A | -135 | -113 | -110 | N/A |
12/31/2023 | 13 | -113 | -107 | -104 | N/A |
9/30/2023 | 67 | -62 | -119 | -117 | N/A |
6/30/2023 | 86 | -28 | -114 | -113 | N/A |
3/31/2023 | 128 | 12 | -115 | -114 | N/A |
12/31/2022 | 268 | 97 | -112 | -111 | N/A |
9/30/2022 | 454 | 261 | -144 | -143 | N/A |
6/30/2022 | 539 | 330 | 490 | 492 | N/A |
3/31/2022 | 497 | 298 | 503 | 504 | N/A |
12/31/2021 | 345 | 215 | 512 | 513 | N/A |
9/30/2021 | 104 | 15 | 565 | 566 | N/A |
6/30/2021 | N/A | -67 | -49 | -49 | N/A |
3/31/2021 | N/A | -50 | -41 | -40 | N/A |
12/31/2020 | N/A | -43 | -26 | -25 | N/A |
9/30/2020 | N/A | -35 | -27 | -27 | N/A |
6/30/2020 | N/A | -31 | -22 | -22 | N/A |
3/31/2020 | N/A | -28 | -18 | -18 | N/A |
12/31/2019 | N/A | -27 | -24 | -23 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ITOS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ITOS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ITOS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ITOS's revenue (64.6% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: ITOS's revenue (64.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ITOS's Return on Equity is forecast to be high in 3 years time